Table 3. Treatment related adverse events.

Effect	Toripalimab (n=23) (%)	Camrelizumab (n=33) (%)	Sintilimab (n=14) (%)	All patients (n=70) (%)
Rash	6 (26.1)	9 (27.3)	4 (28.6)	19 (27.1)
Diarrhea	4 (17.4)	5 (15.2)	3 (21.4)	12 (17.1)
Fatigue	5 (21.7)	4 (12.1)	3 (21.4)	12 (17.1)
Nausea	3 (13.0)	5 (15.2)	3 (21.4)	11 (15.7)
Hepatitis	1 (4.3)	2 (6.1)	1 (7.1)	4 (5.7)
Dyspnea/cough	2 (8.7)	4 (12.1)	1 (7.1)	7 (10.0)
Thyroiditis	0 (0.0)	0 (0.0)	4 (28.6)	4 (5.7)
Renal	1 (4.3)	1 (3.0)	0 (0.0)	2 (2.9)
Amylase/lipase increase	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Ocular toxicity	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Arthritis	2 (8.7)	1 (3.0)	1 (7.1)	4 (5.7)
Myocarditis	0 (0.0)	1 (3.0)	0 (0.0)	1 (1.4)
Myalgia/myositis	1 (4.3)	4 (12.1)	1 (7.1)	6 (8.6)
Paresthesia	2 (8.7)	6 (18.2)	3 (21.4)	11 (15.7)
Hypertension	6 (26.1)	5 (15.2)	2 (14.3)	13 (18.6)
Dental ulcer	2 (8.7)	4 (12.1)	2 (14.3)	8 (11.4)
Hoarseness	1 (4.3)	1 (3.0)	0 (0.0)	2 (2.9)